Novo Seeds portfolio company NorthSea Therapeutics raises US40m in Series B financing
Novo Seeds’ portfolio company, NorthSea Therapeutics a Dutch biotech company developing novel and innovative strategies for the treatment of NASH (Non-alcoholic Steatohepatitis) and other metabolic, inflammatory and fibrotic diseases, has successfully closed a USD40 million (EUR36 million) Series B financing round.The proceeds of this fundraising will be used by NST